Enoxaparin in Children With Asymptomatic Venous Thrombosis After Pediatric Cardiac Surgery
A Randomized Controlled Trial of Enoxaparin in Children With Asymptomatic Venous Thrombosis After Pediatric Cardiac Surgery
The CATCH-enoxaparin trial is the natural continuation of the CATCH study. It will capitalize on the fact that patients enrolled in the CATCH study will be specifically screened for asymptomatic thromboembolism (TEs) in order to answer important clinical questions.
The investigators propose a randomized controlled trial to address whether, among pediatric patients with congenital heart defects (CHD) recovering from cardiovascular surgery and diagnosed with an asymptomatic venous TE, the use of enoxaparin results in a net therapeutic benefit?
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Primary Aim: To address whether, among pediatric patients with congenital heart defects (CHD) recovering from cardiovascular surgery and diagnosed with an asymptomatic venous TE, the use of enoxaparin results in a net therapeutic benefit. We hypothesize that enoxaparin dosed as per age-appropriate algorithms is associated with an increased rate of clot resolution and decreased rate of clot progression/long-term complications in children with CHD and asymptomatic venous TE. Benefits from clot resolution will outweigh the risks associated with the use of enoxaparin resulting in a net therapeutic benefit in favour of enoxaparin use in this context.
Secondary aims of this study are to:
- To compare the rate of conversion from asymptomatic to symptomatic TE and/or thromboembolic events between treated and untreated patients. Hypothesis: the use of enoxaparin will significantly reduce the rate of conversion from asymptomatic to symptomatic TE.
- To compare the rate of objective clot progression (or regression) by serial imaging with ultrasound and echocardiography between treated and untreated patients. Hypothesis: the use of enoxaparin will significantly increase the rate of clot regression.
- To identify factors associated with: TE conversion from asymptomatic to symptomatic, clot resolution and post-thrombotic syndrome in both treated and untreated patients separately. Hypothesis: older children with a more mature coagulation system and those with TEs in superficial vessels (rather than deep/systemic vessels) will have a lower frequency of TE complications.
- To establish the rate of bleeding complications (both minor and major) for patients on enoxaparin. Hypothesis: we expect major bleeding complications to be present in 2-3% of treated patients and minor bleeding complications to be frequent.
Type d'étude
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
Ontario
-
Toronto, Ontario, Canada, M5V1X8
- The Hospital for Sick Children
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Pediatric patients with a cardiac defect (acquired or congenital)
- Recent cardiac surgery (during current hospital admission)3) Presence of a venous clot confirmed by appropriate diagnostic imaging methods associated with either ≥ 25% blood vessel occlusion (clot diameter/vessel diameter) OR is ≥ 3mm in absolute diameter
- Enrollment in the Heart Centre Biobank Registry
- Enrollment in the CATCH main study
Exclusion Criteria:
- Clots associated with any of the following symptoms: swelling, edema, discoloration or high temperature of the affected territory.
- Clots in a vascular segment/location (arterial clots, intracardiac clots) or with a degree of vessel occlusion which obligatory warrants treatment
- Prosthetic heart valve
- Active or previous cancer history
- Known congenital coagulopathy or thrombophilic disorder
- Liver failure (AST, ALT or % bilirubin 2x normal)
- Need for anticoagulation for treatment or prophylaxis for other reasons (e.g. BT shunt, recent thrombosis requiring anticoagulation)
- Previous documented residual clot within the same vascular territory affected by current asymptomatic clot
- Increased bleeding risk reflected by severe thrombocytopenia (platelet count <30,000/ml) and/or coagulopathy (INR >4.0 or aPTT >120s)
- Active bleeding or major bleeding <10 days ago (not surgery related)
- Previous neurosurgery <14 days ago
- Uncontrolled severe hypertension (>95th percentile for age)
- Previous proven diagnosis of heparin-induced-thrombocytopenia (HIT) <100 days ago
- Absolute contraindication to heparin/LMWH (e.g. severe heparin allergy)
- Pregnancy or breastfeeding
- No planned follow-up at The Hospital for Sick Children
While most patients will be identified as part of the CATCH study during the pre-discharge full-body vascular ultrasound, some patients who are not enrolled in CATCH will also be identified if an asymptomatic clot is identified during a clinically indicated radiological study. For those patients who are not already enrolled in the CATCH study and the Heart Centre Biobank Registry, they will be approached and consent will be obtained for those studies prior to enrolment in the CATCH-enoxaparin study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Aucune intervention: Aucun traitement
|
|
|
Expérimental: Treatment group
The initial enoxaparin dose will be: 1.75 mg/kg/dose SC q12h for patients ≤ 2 months old or 1 mg/kg/dose SC q12h for patients > 2 months old Adjust the dose of enoxaparin according to the following monogram. Depending on the Enoxaparin Anti-factor Xa level achieved, successive actions are indicated, including whether to hold the next scheduled dose, whether any dose change is indicated and when the next anti-factor Xa level should be drawn. |
Lovenox- Enoxaparin; Sanofi-Aventis Canada Inc.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Net therapeutic benefit of enoxaparin
Délai: Events recording from baseline to 18 months post-surgery
|
Defined as the between group difference in proportion of patients with negative outcomes (percent clot conversion to symptomatic + percent major bleeding complications)
|
Events recording from baseline to 18 months post-surgery
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Rate of objective clot size progression (or regression)
Délai: Up to 18 months post-surgery
|
This will be determined by serial imaging with ultrasound and frequency of complete clot resolution at the end of the treatment
|
Up to 18 months post-surgery
|
|
Frequency and Risk Factors for conversion from asymptomatic to symptomatic thromboembolism
Délai: Up to 18months post-surgery
|
Defined as the appearance of any of the following symptoms: swelling, edema, discoloration or high temperature of the affected territory
|
Up to 18months post-surgery
|
|
Frequency of and risk factors for post-thrombotic syndrome
Délai: 18 months after surgery
|
Clinical manifestations include varicose veins, edema, skin hyperpigmentation and skin ulcers
|
18 months after surgery
|
|
Frequency of and risk factors for bleeding complications
Délai: Up to 18months
|
Minor complications and major episodes defined as cerebral, abdominal, retroperitoneal or pulmonary hemorrhage or any bleeding complications requiring blood transfusions
|
Up to 18months
|
|
Neurodevelopment and health re-lated quality of life
Délai: 18 months post-surgery
|
Age appropriate PedsQL® generic module and parent report and Child Health Questionnaire
|
18 months post-surgery
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 1000022022
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .